Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

PURPOSE: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti–programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic (PK)–tumor growth dynamics (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Grisic, Ana-Marija, Xiong, Wenyuan, Tanneau, Lénaïg, Jönsson, Siv, Friberg, Lena E., Karlsson, Mats O., Dai, Haiqing, Zheng, Jenny, Girard, Pascal, Khandelwal, Akash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365383/
https://www.ncbi.nlm.nih.gov/pubmed/34921021
http://dx.doi.org/10.1158/1078-0432.CCR-21-2662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365383/
https://www.ncbi.nlm.nih.gov/pubmed/34921021
http://dx.doi.org/10.1158/1078-0432.CCR-21-2662

Ejemplares similares